Jan 4 (Reuters) - Aeterna Zentaris Inc
* Aeterna Zentaris announces top-line results of confirmatory Phase 3 trial of Macrilen
* Aeterna Zentaris Inc says evaluating outcome of trial and will determine in near future whether it will continue with development of Macrilen
* Aeterna Zentaris - results did not meet pre-defined equivalence criteria which required success for percent negative agreement, percent positive agreement
* Aeterna Zentaris - we are “disappointed” regarding outcome of trial, will re-direct resources to completion of on-going Phase 3 clinical trial of zoptrex
* Aeterna Zentaris - trial of Macrilen failed to achieve goal of validating single oral dose of macimorelin for evaluation of AGHD using ITT as comparator Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.